Search results | Endo


Partnering Agreements with Endo Pharmaceuticals

This report provides all the information you require to better understand Endo and its partnering interests and activities over the past seven years

Diagnostic Imaging Partnering Terms and Agreements

The Diagnostic Imaging Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.


Endo Pharmaceuticals

Endo Pharmaceuticals is an American based top pharmaceutical company based in Chadds Ford, Pennsylvania

Bidding war between Teva and Endo for NuPathe

Israel’s Teva Pharmaceutical Industries Ltd offered to buy U.S. neurology drugs maker NuPathe Inc for $114 million plus milestone payments related to NuPathe’s Zecuity migraine treatment.

Endo Pharmaceuticals: M&A activity 2005-2013

Endo Pharmaceuticals has also announced 7 M&A deals since 2005, with the lead deals being the acquisition of MedImmune, Ardea Biosciences and Astra Tech.

Endo Pharmaceuticals: Partnering activity 2005-2013

Endo Health Solutions, a company focused on healthcare solutions operate through it’s companies AMS, Endo Pharmaceuticals, HealthTronics and Qualitest.

Endo Pharmaceuticals: Blending internal R&D, licensing and M&A’s

Endo Pharmaceuticals is a top 50 pharma company specialising in brand pharmaceuticals for the treatment of pain, urology, oncology, CNS and derma products.

Endo may sell one of its divisions in pharma rumor mill

Endo Health Solutions is exploring strategic alternatives for its HealthTronics business and its early-stage drug discovery technology as part of the specialty pharmaceutical company’s effort to focus on its most promising assets.

Endo Pharmaceuticals: Company profile

Endo Pharmaceuticals, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Endo Health in talks with potential pharma partners for its pain relief medication

Endo Health’s talks with potential pharma partners included parties such as Warner Chilcott  and Valeant Pharmaceuticals International Inc  according to the sources. Endo announced in December its longtime chief executive, David Holveck, would retire in 2013.

Dealmakers weekly review – April 23 2012 – GSK, Endocyte, Merck, Aspen, Human Genome Sciences

Partnering gains momentum whilst M&A slows significantly

Dealmakers weekly review – March 12 2012 – Boston Scientific, Cameron Health, Mersana, Endo, Mitsubishi Tanabe, Medicago, Apexigen, Amylin

Partnering slows as bigpharma absent from major dealmaking. Boston Scientific makes move for Cameron Health in $1.35 billion buyout. Financing on the up


Sorry, your search returned no results.


Endo International acquires Par Pharmaceutical

Endo International and Par Pharmaceutical Holdings have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt.

Valeant ups offer and secures Salix; Endo withdraws

Valeant increased the offer price to acquire all the outstanding common stock of Salix from $158.00 per share to $173.00 per share

Endo makes counter bid for Salix

Endo International has submitted a proposal to the Board of Directors of Salix to acquire all of the outstanding shares of common stock of Salix Pharmaceuticals

Boston Scientific acquire men’s health and prostate businesses from Endo

Boston Scientific will acquire Endo’s American Medical Systems’ (AMS) Men’s and Prostate Health businesses for up to $1.65 billion

Endo International sells urology portfolio to Boston Scientific

Endo International is selling its men’s health and prostate urology businesses to Boston Scientific Corp. for $1.6 billion, as it attempts to refocus its efforts on more lucrative parts of its portfolio and regain revenue after a rocky 2014.

Cortendo snags $27.5 million financing

Cortendo has entered agreements with leading U.S. institutional specialist healthcare investors RA Capital Management, New Enterprise Associates (NEA) and Broadfin Capital

Endochoice plans for IPO financing for $150 million

Endochoice is planning a NASDAQ IPO financing for 2015 which it hopes will bring in $100 to $150 Million.

Forendo has announced pharma licensing deal with Apricus

Forendo Pharma has entered into a definitive pharma licensing deal for the US development and commercialization rights for fispemifene to Apricus Biosciences.

M&A news: Auxilium Pharmaceutical joins Endo, rejects QLT

In today’s m&a news, Auxilium Pharmaceutical has agreed to be acquired by Endo International for $2.6 billion, causing it to reject its previously announced merger agreement with QLT for $345 million.

Auxilium rejects M&A bid by Endo for $2.2 billion

M&A news: Endo International has offered $2.2 billion to acquire Canada-based, Auxilium.